| Literature DB >> 24841130 |
Amy R Ellison1, Anna E Savage2, Grace V DiRenzo3, Penny Langhammer4, Karen R Lips3, Kelly R Zamudio5.
Abstract
The emergence of the disease chytridiomycosis caused by the chytrid fungus Batrachochytrium dendrobatidis (Bd) has been implicated in dramatic global amphibian declines. Although many species have undergone catastrophic declines and/or extinctions, others appear to be unaffected or persist at reduced frequencies after Bd outbreaks. The reasons behind this variance in disease outcomes are poorly understood: differences in host immune responses have been proposed, yet previous studies suggest a lack of robust immune responses to Bd in susceptible species. Here, we sequenced transcriptomes from clutch-mates of a highly susceptible amphibian, Atelopus zeteki, with different infection histories. We found significant changes in expression of numerous genes involved in innate and inflammatory responses in infected frogs despite high susceptibility to chytridiomycosis. We show evidence of acquired immune responses generated against Bd, including increased expression of immunoglobulins and major histocompatibility complex genes. In addition, fungal-killing genes had significantly greater expression in frogs previously exposed to Bd compared with Bd-naïve frogs, including chitinase and serine-type proteases. However, our results appear to confirm recent in vitro evidence of immune suppression by Bd, demonstrated by decreased expression of lymphocyte genes in the spleen of infected compared with control frogs. We propose susceptibility to chytridiomycosis is not due to lack of Bd-specific immune responses but instead is caused by failure of those responses to be effective. Ineffective immune pathway activation and timing of antibody production are discussed as potential mechanisms. However, in light of our findings, suppression of key immune responses by Bd is likely an important factor in the lethality of this fungus.Entities:
Keywords: Atelopus zeteki; Batrachochytrium dendrobatidis; acquired immunity; complex genetics; complex immunity; genetics of immunity; immunogenomics; immunosuppression; infection; innate immunity; resistance; tolerance
Mesh:
Substances:
Year: 2014 PMID: 24841130 PMCID: PMC4455776 DOI: 10.1534/g3.114.010744
Source DB: PubMed Journal: G3 (Bethesda) ISSN: 2160-1836 Impact factor: 3.154
Figure 1Number of significant differentially expressed genes among Atelopus zeteki tissues and infection groups. Area-proportional Venn diagrams summarizing the number of significantly differently expressed genes (<0.05 FDR corrected P value) of (A) Atelopus zeteki, (B) among three tissues, and (C) among treatment groups within each tissue. Photo courtesy of Brian Gratwicke.
Figure 2Heatmaps summarizing differential gene expression in Atelopus zeteki. (A) skin, (B) spleen, and (C) small intestine, clustered (via k-means clustering algorithm) by similarity of expression. Each row represents a gene within a minimum FDR-corrected P-value of 0.001 and at least fourfold difference in expression between samples (columns).
Summary of gene cluster expression patterns and overrepresented GO terms
| Cluster | Expression Pattern | No. of Genes (No. Annotated) | No. of Overrepresented GO Terms | Examples of Overrepresented GO Terms | ||
|---|---|---|---|---|---|---|
| Control | Naïve | Survived | ||||
| Skin | ||||||
| SK1 | −1.1 | +1.1 | +0.5 | 1395 (654) | 364 | Response to fungus, humoral immune response mediated by circulating immunoglobulin, B-cell activation involved in immune response, cytokine secretion, leukocyte migration |
| SK2 | +2.4 | −2.7 | −0.7 | 129 (55) | 13 | Water transport, keratinocyte differentiation, cellular response to metal ion |
| SK3 | +2.3 | −2.3 | −1.1 | 349 (172) | 20 | Inflammatory response, immune response, defense response to bacterium, response to Lipopolysaccharide, response to cytokine stimulus |
| SK4 | +1.1 | −1.0 | −0.7 | 755 (475) | 58 | Epithelial cell proliferation, collagen fibril organization, electron transport, DNA replication, heme |
| Catabolic process | ||||||
| Spleen | ||||||
| SP1 | −0.8 | +1.1 | −0.1 | 373 (222) | 8 | Immune response, response to chemical stimulus |
| SP2 | −0.6 | −0.2 | +1.8 | 187 (104) | 0 | No significant enrichment |
| SP3 | −1.5 | −1.5 | +6.9 | 42 (39) | 19 | Proteolysis, serine-type endopeptidase activity, metallocarboxypeptidase activity, hydrolase activity |
| SP4 | −1.3 | +1.2 | +0.9 | 308 (168) | 21 | Cell communication, response to hypoxia, circulatory system development, signaling |
| SP5 | +1.6 | −1.5 | −1.2 | 108 (55) | 64 | Oxygen transport, immune system development, cellular ion homeostasis, Gamma-delta T-cell activation, gamma-delta T-cell differentiation |
| SP6 | +1.0 | −0.8 | −0.8 | 301 (166) | 16 | Alpha-beta T-cell differentiation, cytokine production, regulation of cell activation, hemopoiesis |
| Intestine | ||||||
| I1 | −1.8 | +1.2 | +2.2 | 23 (23) | 23 | Serine-type peptidase activity, proteolysis, collagen catabolic process, metalloexopeptidase activity |
| I2 | +1.2 | −1.2 | −0.5 | 117 (76) | 21 | Oxidation-reduction process, lipid metabolic process, monosaccharide metabolic process |
| I3 | +0.8 | −0.6 | −0.7 | 225 (93) | 0 | No significant enrichment |
| I4 | −1.5 | +1.6 | +0.5 | 103 (53) | 0 | No significant enrichment |
| I5 | +0.9 | −0.7 | −0.9 | 152 (107) | 57 | Mitotic cell cycle, protein folding in endoplasmic reticulum, DNA replication, regulation of nuclease activity, chromosome organization |
| I6 | −0.8 | +1.0 | 0.0 | 234 (166) | 58 | Immune system development, programmed cell death, regulation of response to stress, chronic inflammatory response, signal transduction |
Clusters defined by k-means clustering.
Average log2-fold change.
Full list of overrepresented GO terms are provided in Table S1.
Control uninfected.
Bd-naïve infected.
Previously survived Bd infected.
Number of differentially expressed immune-related genes and percentage with expression increases in three tissues of Atelopus zeteki
| Category (Tissue) | Naïve | Survived | Naïve | |||
|---|---|---|---|---|---|---|
| No. | % up | No. | % up | No. | % up | |
| B cells | ||||||
| Skin | 16 | 75.0 | 5 | 80.0 | 1 | 100.0 |
| Spleen | 18 | 38.9 | 15 | 40.0 | 1 | 100.0 |
| Intestine | 6 | 83.3 | 3 | 100.0 | 1 | 100.0 |
| Complement | ||||||
| Skin | 16 | 81.3 | 13 | 92.3 | 0 | − |
| Spleen | 16 | 100.0 | 7 | 100.0 | 2 | 50.0 |
| Intestine | 6 | 100.0 | 4 | 25.0 | 0 | − |
| Immunoglobulins | ||||||
| Skin | 8 | 75.0 | 9 | 88.9 | 4 | 0.0 |
| Spleen | 20 | 80.0 | 9 | 77.8 | 3 | 100.0 |
| Intestine | 3 | 100.0 | 1 | 100.0 | 0 | − |
| Interferons | ||||||
| Skin | 27 | 96.3 | 17 | 100.0 | 0 | − |
| Spleen | 17 | 35.3 | 22 | 18.2 | 0 | − |
| Intestine | 10 | 100.0 | 4 | 100.0 | 0 | − |
| Interleukins | ||||||
| Skin | 36 | 91.7 | 19 | 94.7 | 8 | 87.5 |
| Spleen | 24 | 70.8 | 11 | 36.4 | 4 | 100.0 |
| Intestine | 11 | 100.0 | 4 | 100.0 | 0 | − |
| Macrophages | ||||||
| Skin | 8 | 75.0 | 6 | 83.3 | 1 | 100.0 |
| Spleen | 10 | 80.0 | 5 | 40.0 | 2 | 100.0 |
| Intestine | 6 | 66.7 | 0 | − | 0 | − |
| Major and minor histocompatibility | ||||||
| Skin | 3 | 100.0 | 6 | 100.0 | 0 | − |
| Spleen | 3 | 33.3 | 4 | 75.0 | 0 | − |
| Intestine | 0 | − | 0 | − | 0 | − |
| Nuclear factor-κβ | ||||||
| Skin | 6 | 100.0 | 4 | 100.0 | 0 | − |
| Spleen | 4 | 100.0 | 2 | 100.0 | 0 | − |
| Intestine | 2 | 100.0 | 1 | 0.0 | 0 | − |
| Toll-like receptors | ||||||
| Skin | 6 | 66.7 | 2 | 100.0 | 0 | − |
| Spleen | 6 | 100.0 | 3 | 33.3 | 1 | 100.0 |
| Intestine | 3 | 66.7 | 0 | − | 1 | 100.0 |
| Tumor necrosis factors | ||||||
| Skin | 28 | 92.9 | 17 | 100.0 | 3 | 100.0 |
| Spleen | 20 | 80.0 | 15 | 66.7 | 1 | 100.0 |
| Intestine | 16 | 87.5 | 7 | 71.4 | 0 | − |
| T cells | ||||||
| Skin | 8 | 75.0 | 3 | 33.3 | 0 | − |
| Spleen | 35 | 17.1 | 30 | 10.0 | 0 | − |
| Intestine | 4 | 50.0 | 1 | 0.0 | 0 | − |
| Other cytokines | ||||||
| Skin | 16 | 93.8 | 9 | 77.8 | 1 | 100.0 |
| Spleen | 18 | 72.2 | 12 | 41.7 | 4 | 75.0 |
| Intestine | 6 | 100.0 | 3 | 100.0 | 0 | − |
| Other immune-related genes | ||||||
| Skin | 22 | 90.9 | 16 | 87.5 | 3 | 66.7 |
| Spleen | 19 | 63.2 | 18 | 44.4 | 7 | 57.1 |
| Intestine | 12 | 75.0 | 6 | 100.0 | 2 | 100.0 |
A complete list of genes, fold-changes, and significance is available in Table S2, Table S3, and Table S4. Control, uninfected control; naïve, Bd-naïve infected; survived, previously survived Bd infected.
Figure 3Differential gene expression of chitinase 1 in Atelopus zeteki. Results of exact tests for expression differences measured by fragments per kilobases per million mapped (FPKM), in chitinase 1 gene in three tissues of Atelopus zeteki. Letters indicate significant differences among treatment groups (no significant difference among groups with same letter, FDR corrected P-value <0.05) and error bars represent ± 1 SE.
T -cell receptor gene expression differences
| Contig ID | Description | Log2-Fold Change | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Naïve Infected | Survived Infected | ||||||||||||
| Skin | Spleen | Intestine | Skin | Spleen | Intestine | ||||||||
| comp185333_c1 | T-cell receptor alpha chain | ||||||||||||
| comp100948_c0 | T-cell receptor alpha chain | ||||||||||||
| comp136812_c0 | T-cell receptor alpha chain | ||||||||||||
| comp183357_c0 | T-cell receptor alpha chain v region | ||||||||||||
| comp186997_c2 | T-cell receptor beta | +3.21 | |||||||||||
| comp193946_c0 | T-cell receptor beta variable 19 | ||||||||||||
| comp153538_c0 | T-cell receptor beta chain | ||||||||||||
| comp151427_c0 | T-cell receptor beta chain | ||||||||||||
| comp137067_c0 | T-cell receptor beta chain | ||||||||||||
| comp167921_c0 | T-cell receptor beta chain | ||||||||||||
| comp153207_c0 | T-cell receptor beta chain | ||||||||||||
| comp164781_c0 | T-cell receptor beta chain | ||||||||||||
| comp100980_c0 | T-cell receptor beta chain | ||||||||||||
| comp148731_c0 | T-cell receptor beta chain | ||||||||||||
| comp172614_c0 | T-cell receptor delta chain | +2.00 | |||||||||||
| comp180632_c0 | T-cell receptor delta chain | ||||||||||||
| comp176041_c0 | T-cell receptor gamma chain | ||||||||||||
| comp178628_c0 | T-cell receptor gamma chain | ||||||||||||
| comp159481_c0 | CD3e epsilon (CD3-TCR complex) | +3.57 | |||||||||||
| comp185118_c0 | CD4 precursor | +2.00 | +1.51 | ||||||||||
| comp171746_c0 | CD8 alpha | ||||||||||||
| comp180074_c0 | CD8 beta | +0.87 | |||||||||||
Comparisons between uninfected (control) and infected (naïve vs. control and survived vs. control) Atelopus zeteki. P values after FDR correction for multiple tests. Significant decreases in expression are highlighted in bold. FDR, false-discovery rate.
Figure 4Differential gene expression of immunoglobulin heavy chain constant region in Atelopus zeteki. Results of exact tests for expression differences, measured by fragments per kilobases per million mapped (FPKM) in immunoglobulin heavy chain constant region in three tissues of Atelopus zeteki. Letters indicate significant differences among treatment groups (no significant difference among groups with same letter, FDR corrected P value <0.05) and error bars represent ± 1 SE.